



General description

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

INN	Bevacizumab
ATC codes	S01LA08
Medicine type	Biological agent
EML status history	First added in 2013 (TRS 985) for Age related macular degeneration
Wikipedia	Bevacizumab ↗
DrugBank	Bevacizumab ↗

Recommendations

Section Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age related macular degeneration

